Abstracts tagged "C-reactive protein (CRP)"

Abstract Number: 340 • 2019 ACR/ARP Annual Meeting
Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels
Naomi Schlesinger¹, Kyle Jablonski ², Peter Harb ³, Caitlin Henry ³, Emily Schwarz ³, Ifeoma Okafor ³, Wael Jarjour ⁴ and Nicholas Young ⁵, ¹Rutgers Health- RWJ Medical School, New Brunswick, NJ, ²The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, ³Ohio State College of Medicine, Columbus, ⁴Ohio State College of Medicine, Columbus, OH, ⁵The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH
Background/Purpose: Regular exercise programs were previously thought to be inappropriate in patients with rheumatic diseases because of the potential to exacerbate inflammation. However, while recent paradigm-shifting…
Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting
Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)
Christine Xu¹, Patrick Nolain ², Qiang Lu ³, Anne Paccaly ⁴, Melitza Iglesias-Rodriguez ⁵, Gregory St John ⁶, Chad Nivens ⁴, Rafael Maldonado ⁷, Tomonori Ishii ⁸, Ernest Choy ⁹ and Vanaja Kanamaluru ³, ¹Sanofi, Bridgewater, NJ, ²Sanofi-Aventis, Montpellier, France, ³Sanofi, Bridgewater, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Pompeu Fabra University, Barcelona, Spain, ⁸Tohoku University Hospital, Sendai, Japan, ⁹Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…
Abstract Number: 1509 • 2019 ACR/ARP Annual Meeting
Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Atul Deodhar¹, Philip Mease ², Paula Machado ³, Xiangyi Meng ³, Vibeke Strand ⁴ and Marina Magrey ⁵, ¹Oregon Health & Science University, Portland, OR, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁵Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS), a chronic inflammatory disease involving the sacroiliac joints and spine, is associated with pain, stiffness, disability, and reduced quality of life.1,2…
Abstract Number: 2458 • 2019 ACR/ARP Annual Meeting
Predictors of Structural Progression in Psoriatic Arthritis: Clinical versus Systemic Inflammation
Carina Borst¹, Farideh Alasti ² and Daniel Aletaha ³, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria
Background/Purpose: Psoriatic arthritis (PsA) belongs to the group of the spondylarthropathies. It is associated with psoriasis and typically seronegative for autoantibodies. PsA disease activity can…
Abstract Number: 589 • 2018 ACR/ARHP Annual Meeting
DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: In most patients with rheumatoid arthritis (RA) the 28-Joint Disease Activity Score (DAS28) values calculated using C-reactive protein (CRP) are lower than those calculated…
Abstract Number: 649 • 2018 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on a Quick Quantitative CRP Assay Performs Similarly Well to ASDAS Based on Conventional CRP in Patients with Axial Spondyloarthritis
Fabian Proft¹, Burkhard Muche¹, Laura Spiller¹, Valeria Rios Rodriguez¹, Judith Rademacher¹, Anne-Katrin Weber¹, Susanne Lueders², Mikhail Protopopov¹, Inge Spiller¹, Joachim Sieper³ and Denis Poddubnyy^3,4, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁴German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index to assess disease activity in patients with axial spondyloarthritis (axSpA). According to the…
Abstract Number: 1326 • 2018 ACR/ARHP Annual Meeting
Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with Familial Mediterranean Fever ?
Serdal Ugurlu¹, Oguzhan Selvi², Bilgesu Ergezen¹ and Huri Ozdogan¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: In order to follow subclinical inflammation and adjust the therapy for an optimal disease control, clinicians seek for readily accessible, affordable and reproducible markers.…
Abstract Number: 1530 • 2018 ACR/ARHP Annual Meeting
CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
Oliver Hendricks¹, Stavros Chrysidis², Jens Gerwien³, Chadi Saifan³, Francesco de Leonardis³, Pedro Lopez-Romero³, Jinglin Zhong⁴, Kevin Winthrop⁵ and Josef S. Smolen⁶, ¹King Chr.Xs Rheumatology Hospital, Graasten, Denmark, ²Rheumatology Department Sydvestjysk Sygehus, Esbjerg, Denmark, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Rockville, MD, ⁵Oregon Health Sciences University, Portland, OR, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (BARI) is a selective inhibitor of Janus kinase 1/2, modulating responses to inflammatory cytokines, e.g. IL-6 or IFNs1. During acute inflammation, including those…
Abstract Number: 2619 • 2018 ACR/ARHP Annual Meeting
Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis
Lesley Jackson¹, Jeffry Bieber^1,2 and R. Eric Heidel³, ¹Graduate School of Medicine, Department of Internal Medicine, University of Tennessee Medical Center Knoxville, Knoxville, TN, ²UT Rheumatology, Knoxville, TN, ³Graduate School of Medicine, Division of Biostatistics, and Department of Surgery, University of Tennessee Medical Center Knoxville, Knoxville, TN
Background/Purpose: It is well established that psoriatic arthritis is associated with increased cardiovascular disease risk. The use of statins may impart anti-inflammatory effects, possibly through…
Abstract Number: 2506 • 2017 ACR/ARHP Annual Meeting
In Ankylosing Spondylitis/Axial Spondyloarthritis Smoking Is Associated with a Dose Related Elevation in CRP, Worse Disease Activity and Worse Quality of Life over One Year
Simon Stebbings¹, Mary Wallace², Andrew A. Harrison³, Nicola Dalbeth⁴, Douglas White⁵, Lisa K. Stamp⁶, Daniel Ching⁷ and John Highton⁸, ¹Dunedin Hospital, Department of Rheumatology, Dunedin, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵Department of Rheumatology, Waikato Clinical School, Hamilton, New Zealand, ⁶University of Otago, Christchurch, New Zealand, ⁷Timaru Medical Specialists Ltd, Timaru, New Zealand, ⁸Dept of Medicine, Univ of Otago Med Sch, Dunedin, New Zealand
Background/Purpose: Analysis of data from several cohort studies of patients with ankylosing spondylitis (AS) /axial spondyloarthritis (AxSpA) have confirmed earlier suggestions that current smokers have…
Abstract Number: 537 • 2017 ACR/ARHP Annual Meeting
No Effect of Baseline Serum CRP Levels on Clinical Efficacy Parameters in Rheumatoid Arthritis Patients Treated with Filgotinib: Post Hoc Analysis from Two Phase 2B Studies
Arthur Kavanaugh¹, Annegret Van der Aa², Corinne Jamoul², Chantal Tasset², Pille Harrison² and René Westhovens³, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Galapagos NV, Mechelen, Belgium, ³Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium
Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…
Abstract Number: 1352 • 2017 ACR/ARHP Annual Meeting
The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis
Craig Scoville¹, Jessica L. Suboticki², Sheng Zhong³ and Edward C. Keystone⁴, ¹Idaho Falls Arthritis Clinic, Idaho Falls, ID, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Elevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) with rheumatoid arthritis (RA) patients (pts), resulting in the…
Abstract Number: 1437 • 2017 ACR/ARHP Annual Meeting
C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial
Roy Fleischmann¹, Carol A Connell², Haiyun Fan³ and Sander Strengholt⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Capelle aan den IJssel, Netherlands
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We examined high sensitivity C-reactive protein (hsCRP) levels in relation…
Abstract Number: 1523 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies
Jürgen Braun¹, Joachim Sieper², Robert B.M. Landewé³, Xenofon Baraliakos¹, Corinne Miceli-Richard⁴, Ruvie Martin⁵, Brian Porter⁵, Kunal Gandhi⁵ and Désirée van der Heijde⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, Hôpital Bicêtre, Paris, France, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inhibition of IL-17A with secukinumab is an approved therapy for patients (pts) with AS.1 It has been previously reported that response rates with TNFα…
Abstract Number: 1954 • 2017 ACR/ARHP Annual Meeting
Association of CRP with BMI in Males and Females
Taik Kim¹, Stephen J. Ganocy², Maria Antonelli³, Douglas Einstadter⁴ and Stanley Ballou¹, ¹Rheumatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Department of Medicine/Division of Rheumatology, Case Western Reserve University School of Medicine, MetroHealth Medical Center, Cleveland, OH, ⁴Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: C-reactive Protein (CRP) is an inflammatory marker commonly used to help aid in diagnosis, assess disease activity or monitor response to therapy. It is…